Navigation Links
Hamner Institutes and UNC Launch International Drug Safety Institute
Date:6/15/2009

Scientific Collaboration Aims At Improving Drug Safety, Advancing Drug Development

RESEARCH TRIANGLE PARK, N.C., June 15 /PRNewswire/ -- The Hamner Institutes for Health Sciences and the University of North Carolina at Chapel Hill have announced the launch of The Institute for Drug Safety Sciences, strategically located on The Hamner's 56-acre campus in RTP. The Institute will be led by Dr. Paul Watkins, one of the world's leading experts in drug-induced liver injury who currently serves as the Verne S. Caviness Distinguished Professor of Medicine at UNC. As founding director for this innovative research Institute, Watkins has assembled a core group of internal scientists and academic partners to develop new global drug safety initiatives in collaboration with the bio/pharmaceutical industry, the NIH and FDA. A major initial focus will be to develop new computational models and in vitro assays, starting with evaluating liver toxicity and expanding into cardiovascular and kidney drug side effects.

The Institute for Drug Safety Sciences, which includes a 14,000-square-foot, state-of-the-art research laboratory, was unveiled at a grand opening on June 11. The event featured a keynote from Janet Woodcock, Director of FDA's Center for Drug Evaluation and Research, which oversees the approval and regulation of all U.S. medications. The June 11 event built on a MOU signed by The Hamner and UNC in April 2008 and a $10M funding commitment established in September 2008. The Hamner-UNC partnership capitalizes on the scientific strengths of a leading university and an independent research institute, which are committed to accelerating advances in human therapeutics and public health, both in N.C. and internationally.

In March 2009, scientists at the Institute for Drug Safety Sciences launched their first research initiative in the study of drug-induced liver injury by forming a partnership with Entelos, a leading Silicon Valley computational modeling company. Besides being a main cause of acute liver failure in the U.S., liver toxicity is also the major reason global regulatory agencies take action on drugs, including denying approval for drug development candidates or withdrawing drugs from the marketplace. By creating a virtual liver model, researchers hope to predict how pharmaceutical drugs and chemical agents damage the liver. The project supports the FDA's "Critical Path Initiative," which aims to reduce the time it takes to develop and approve safe and effective medical products.

The Institute for Drug Safety Sciences has also signed an agreement with the Shanghai Center for Disease Control to conduct a study in patients who have experienced liver toxicity as a result of taking drugs to treat tuberculosis. Knowledge from this study in China will enable the Institute to create strategies to develop safer drugs in the U.S., China, and worldwide. Recently, The Hamner announced a translational research and business development partnership with China Medical City and Newsummit Biopharma to establish an Institute for International Drug Development to further enhance the process of taking drugs from the "bench to the bedside."

For more information, visit www.thehamner.org.

    Ryal Curtis
    MMI Associates, Inc.
    919-233-6600
    ryal@mmimarketing.com


'/>"/>
SOURCE The Hamner Institutes for Health Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
2. Thomson Scientific Ranks Australian Universities and Research Institutes
3. Rhode Island Hospital lands $11.1M grant from National Institutes of Health
4. $6.37 million from National Institutes of Health to find new ways to treat psoriasis
5. National Institutes of Health selects Childrens Hospital Oakland for grant award
6. National Institutes of Health grant to fund drug abuse research at UH
7. National Institutes of Health funds new center for reproduction and infertility research at Illinois
8. National Institutes of Health Appoints Timothy C. Birdsall, ND to CAM Advisory Council
9. Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims
10. Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant
11. How to Help Down Syndrome and Other Special Needs Children - Free Booklet and Parenting Course Available This Month From The Institutes for the Achievement of Human Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and ... who do not do their research and undergo cosmetic dermatology treatments from unqualified practitioners ... of a renaissance and every other month a new treatment or device is launched, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... innovative, personalized cell-based treatment for a high-risk form of the most common ... Hospital of Philadelphia today reported new results using ... The physician-scientists presented findings at the annual meeting of the American ... Continue Reading ... ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... newsletter to their offering. ... , , R&D Drug ... Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online access to ... on the market and on investigational drug candidates in research & ...
(Date:12/2/2016)... Columbia , December 2, 2016 - bioLytical lanza el ... nuevas directrices de la OMS     Continue Reading ... ... , , ... enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su INSTI ...
Breaking Medicine Technology: